{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:08:36Z","timestamp":1791389316725,"version":"4.3.3"},"update-to":[{"DOI":"10.1002\/14651858.cd006455","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2009,7,8]],"date-time":"2009-07-08T00:00:00Z","timestamp":1247011200000}}],"reference-count":41,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006455.pub2","type":"journal-article","created":{"date-parts":[[2009,7,3]],"date-time":"2009-07-03T11:05:03Z","timestamp":1246619103000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Therapeutic interventions for disease progression in Huntington's disease"],"prefix":"10.1002","author":[{"given":"Tiago","family":"Mestre","sequence":"first","affiliation":[{"name":"Institute of Molecular Medicine; Neurological Clinical Research Unit; Hospital de Santa Maria Av. Prof. Egas Moniz Lisboa Portugal 1649-028"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina de Lisboa; Laborat\u00f3rio de Farmacologia Cl\u00ednica e Terap\u00eautica; Hospital de Santa Maria Av. Prof. Egas Moniz Lisboa Portugal 1649-028"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel M","family":"Coelho","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina de Lisboa; Laborat\u00f3rio de Farmacologia Cl\u00ednica e Terap\u00eautica; Hospital de Santa Maria Av. Prof. Egas Moniz Lisboa Portugal 1649-028"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rio","family":"Rosa","sequence":"additional","affiliation":[{"name":"Institute of Molecular Medicine; Neurological Clinical Research Unit; Hospital de Santa Maria Av. Prof. Egas Moniz Lisboa Portugal 1649-028"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sampaio","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina de Lisboa; Laborat\u00f3rio de Farmacologia Cl\u00ednica e Terap\u00eautica; Hospital de Santa Maria Av. Prof. Egas Moniz Lisboa Portugal 1649-028"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,7,8]]},"reference":[{"key":"10.1002\/14651858.CD006455.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/WNL.57.3.397","article-title":"A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease","volume":"57(3)","author":"The Huntington study group","year":"2001","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0002|cit2","first-page":"262","article-title":"Riluzole in Huntington\u00b4s disease: a 3 year, randomised controlled study","volume":"62(3)","author":"European Huntington Disease Initiative Study Group","year":"2007","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1212\/WNL.53.5.1000","article-title":"Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial","volume":"53(5)","author":"Kremer","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0004|cit4","first-page":"1771","article-title":"Trial of d-alpha-tocopherol in Huntington's disease","volume":"152(12)","author":"Peyser","year":"1995","journal-title":"Am J Psychiatry"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1212\/01.wnl.0000169025.09670.6d","article-title":"Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial","volume":"65(2)","author":"Puri","year":"2005","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/mds.870110510","article-title":"A controlled trial of idebenone in Huntington's disease","volume":"11(5)","author":"Ranen","year":"1996","journal-title":"Mov Disord"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/ana.410250308","article-title":"A controlled clinical trial of baclofen as protective therapy in early Huntington's disease","volume":"25(3)","author":"Shoulson","year":"1989","journal-title":"Ann Neurol"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1212\/01.WNL.0000090629.40891.4B","article-title":"Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial","volume":"61(7)","author":"Verbessem","year":"2003","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD006455.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1006\/exnr.1999.7239","article-title":"Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease","volume":"161","author":"Bachoud-L\u00e9vi","year":"2000","journal-title":"Exp Neurol"},{"issue":"9246","key":"10.1002\/14651858.CD006455.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(00)03310-9","article-title":"Motor and cognitive improvements in patients with Huntington's disease after neural transplantation","volume":"356","author":"Bachoud-L\u00e9vi","year":"2000","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1474-4422(06)70381-7","article-title":"Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study","volume":"5(4)","author":"Bachoud-L\u00e9vi","year":"2006","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-7091-0579-5_14","article-title":"The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease","volume":"68","author":"Beister","year":"2004","journal-title":"J Neural Transm Suppl"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00415-005-0595-4","article-title":"Creatine supplementation lowers brain glutamate levels in Huntington's disease","volume":"252(1)","author":"Bender","year":"2005","journal-title":"J Neurol."},{"key":"10.1002\/14651858.CD006455.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1089\/hum.2004.15.968","article-title":"Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study","volume":"15(10)","author":"Bloch","year":"2004","journal-title":"Hum Gene Ther"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1212\/01.WNL.0000049936.85487.7A","article-title":"Minocycline for Huntington's disease: an open label study","volume":"60(5)","author":"Bonelli","year":"2003","journal-title":"Neurology."},{"key":"10.1002\/14651858.CD006455.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00004850-200411000-00004","article-title":"Neuroprotection in Huntington's disease: a 2-year study on minocycline","volume":"19(6)","author":"Bonelli","year":"2004","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/bmj.1.6116.859-c","article-title":"Vitamin E in treatment of Huntington's chorea","volume":"1(6116)","author":"Caro","year":"1978","journal-title":"Br Med J"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/mds.20756","article-title":"CTYE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease","volume":"21(4)","author":"Dubinsky","year":"2006","journal-title":"Mov Disord"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0019|cit19","first-page":"312","article-title":"Assessment of coenzyme Q10 tolerability in Huntington's disease","volume":"11(3)","author":"Feigin","year":"1996","journal-title":"Mov Disord"},{"issue":"2","key":"10.1002\/14651858.CD006455.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/096368970000900212","article-title":"Porcine xenografts in Parkinson's disease and Huntington's disease patients:preliminary results","volume":"9","author":"Fink","year":"2000","journal-title":"Cell Transplant"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1212\/WNL.58.5.687","article-title":"Bilateral human fetal striatal transplantation in Huntington's disease","volume":"58(5)","author":"Hauser","year":"2002","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00001756-200201210-00029","article-title":"MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment","volume":"13(1)","author":"Puri","year":"2002","journal-title":"Neuroreport."},{"key":"10.1002\/14651858.CD006455.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/1531-8257(199903)14:2<326::AID-MDS1019>3.0.CO;2-Q","article-title":"Riluzole therapy in Huntington's disease (HD)","volume":"14(2)","author":"Rosas","year":"1999","journal-title":"Mov Disord"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1212\/01.WNL.0000070186.97463.A7","article-title":"Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study","volume":"Jul 8;61(1)","author":"Tabrizi","year":"2003","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1212\/01.WNL.0000160388.96242.77","article-title":"High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study","volume":"64(9)","author":"Tabrizi","year":"2005","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006455.pub2-BIB0026|cit26","first-page":"510","article-title":"Minocycline in Huntington\u00b4s disease: a pilot study","volume":"20","author":"Thomas","year":"2004","journal-title":"Movement disorders"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0027|cit27","unstructured":"Coenzyme Q10 in Huntington's Disease. Ongoing study March 2008."},{"key":"10.1002\/14651858.CD006455.pub2-BIB0028|cit28","unstructured":"A Multi-Center, Double-Blind, Pilot Study of Minocycline in Huntington's Disease. Ongoing study January 2006."},{"key":"10.1002\/14651858.CD006455.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00004850-200403000-00001","article-title":"Huntington's disease: present treatments and future therapeutic modalities","volume":"19 (2)","author":"Bonelli","year":"2004","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0030|cit30","unstructured":"www.cochrane.org\/resources\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD006455.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mds.870110204","article-title":"Unified Huntington's disease rating scale: Reliability and consistency","volume":"11","author":"Huntington Study Group","year":"1996","journal-title":"Movement Disorders"},{"issue":"(1)","key":"10.1002\/14651858.CD006455.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1136\/jmg.31.11.872","article-title":"Trinucleotide repeat length and progression of illness in Huntington's disease","volume":"1 (11)","author":"Kieburtz","year":"1994","journal-title":"J Med Genet,"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/088307389501000112","article-title":"George Huntington and hereditary chorea","volume":"10 (1)","author":"Lanska","year":"1995","journal-title":"J Child Neurol"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0035|cit35","unstructured":"European Huntingotn Disease Network World Congress in Huntington's disease 2007"},{"issue":"8","key":"10.1002\/14651858.CD006455.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/jnnp.2007.128728","article-title":"Detection of Huntington's disease decades before diagnosis: The Predict HD study","volume":"79","author":"Paulsen","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0037|cit37","unstructured":"Review Manager (RevMan) [MacOSX]. Version 5.0. Copenhagen: The Nordic Cochrane Centre The Cochrane Collaboration 2008"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0038|cit38","volume-title":"Principles of Neurology","author":"Ropper","year":"2005"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosome","volume":"72","author":"TH.s.DCR","year":"1993","journal-title":"Cell"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0040|cit40","unstructured":"http:\/\/www.track-hd.net"},{"key":"10.1002\/14651858.CD006455.pub2-BIB0041|cit41","unstructured":"The Huntington Study group TREND-HD - A Trial of Ethyl-EPA (Miraxion\u2122) in Treating Mild to Moderate Huntington's Disease World Congress in Huntington's disease 2007"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD006455.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:58:53Z","timestamp":1710464333000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006455.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Movement Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2009,7,8]]},"references-count":41,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006455.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,8]]}}}